http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-068102-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 |
| filingDate | 2008-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe98bf148d556fecdd2e9d818c8a7726 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb76c60487c2c0ac4c44b6328260640e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64c252397804123d7b339fb173296d12 |
| publicationDate | 2009-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-068102-A1 |
| titleOfInvention | PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-O-GLUCOSIDO |
| abstract | A pharmaceutical composition comprising a pyrazole-O-glucoside derivative in combination with a DPP IV inhibitor in the treatment or prevention of one or more related conditions of type 1 diabetes mellitus, type 2 diabetes mellitus, abnormal glucose tolerance and hyperglycemia. Methods to prevent or treat metabolic disorders and related conditions. Claim 1: A pharmaceutical composition characterized in that it comprises a pyrazole-O-glucoside derivative of formula (1) wherein R1 indicates C1-3 alkoxy; L1, L2, independently of each other, indicate H or F; R6 indicates H, (C1-3 alkyl) carbonyl, (C1-6 alkyl) oxycarbony, phenyloxycarbonyl, benzyloxycarbonyl or benzylcarbonyl; in combination with a DPP IV inhibitor selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, alogliptin, denagliptin, (2S) -1 - {[2- (5-methyl-2-phenyloxazol-4-yl) ethylamino] acetyl } pyrrolidin-2-carbonitrile, (2S) -1 - {[1,1-dimethyl-3- (4-pyridin-3-unlimitedidazol-1-yl) propylamino] acetyl} pyrrolidin-2-carbonitrile, (S) - 1 - ((2S, 3S, 11bS) -2-amino-9,10-dimethoxy-1,3,4,7,11b-hexahydro-2H-pyrido [2,1-a] isoquinolin-3-yl) - 4-fluoromethylpyrrolidin-2-one, (3,3-difluoropyrrolidin-1-yl) - ((2S, 4S) -4- (4- (pyrimidin-2-iI) piperazin-1-yl) pyrrolidin-2-yl ) methanone, (1 - ((3S, 4S) -4-amino-1- (4- (3,3-difIuoropyrrolidin-1-yl) -1,3,5-triazin-2-iI) pyrrolidin-3- il) -5,5-difluoropiperidin-2-one, (2S, 4S) -1- {2 - [(3S, 1R) -3- (1H-1,2,4-triazol-1-ylmethyl) cyclopentylamino] acetyl} -4-fluoropyrrolidin-2-carbonitrile, and 2- [6- (3-aminopiperidin-1-yl) -3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl ] -4-fluorobenzonitrile, or its pharmaceutically acceptable salt. |
| priorityDate | 2007-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.